Urology
Innovative reporting for prostate and bladder cancer
Partners in Pathology with Patient-Centric Care
QDx provides a full range of tests and pathology services focused on supporting your screening, diagnostic and case management strategy. Our pathologists are ready to collaborate with you on identifying the right pathway forward for successful clinical outcomes.
Cystoscopy examination of the bladder, and often urine cytology, are standard care for patients >40 years of age and presenting with hematuria.4 QDx provides the pathology and testing services to support screening, recurrence monitoring and detection of bladder cancer.
FISH BLADDER CANCER SCREENING
Patients with hematuria and suspected of having bladder cancer should be screened with FISH test as a complimentary procedure to a cytopathology examination. QDx utilizes the FDA approved Abbott UroVysion test kit to detect bladder cancer in urine. The fluorescence in situ hybridization assay utilizes fluorescently labeled DNA probes. The method quantifies aneuploidy chromosomes 3, 7, 17, and the loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine samples.
BLADDER CANCER PATHOLOGY EXAMINATION
QDx Pathologists provide pathology examination and interpretation of bladder cells utilizing special stains and select IHC stains. QDx employs pathologists with uropathology specialization and training. When necessary, our pathologists provide personalized consultations to the referring provider.
Diagnostic services cover a variety of bladder cancers including:
- Urothelial Carcinoma (transitional cell carcinoma) TCC
- Squamous Cell Carcinoma
- Adenocarcinoma
- Small Cell Carcinoma
- Sarcoma
- Carcinoma in Situ (CIS)
- Metastatic Carcinoma
URO FISH REPORT
BLADDER PATHOLOGY REPORT
4.Grossfeld GD, Wolf JS, Litwin MS, et al. Asymptomatic Microscopic Hematuria in Adults: summary of AUA best practice policy recommendations. Am Fam Phys. 2001;63(6):1145-1154
Prostate cancer is the second leading cancer diagnosis in men with 268,000 new cases diagnosed each in the United States.1 The QDx pathology team provides expert evaluation to inform treatment strategy.
QDx pathologists employ H&E and IHC stains to support their evaluation of prostate tumors. Final reports include pathologist interpretation, Gleason grading score, Partin table and graphical representation of the tumor location.
GLEASON GRADING
QDx pathologists determine and report a Gleason score for each tumor by evaluating and grading the tumor in comparison with normal prostate glands. Higher scores reflect increasingly complicated glandular proliferations.
SCORING METHODOLOGY
The pathologist grades each sample of prostate cancer cells from 3 to 5 based on how quickly they are likely to grow or how aggressive the cells look. The scoring outline and report examples are listed below.
PARTIN TABLE
QDx includes a Partin table in its prostate pathology report which includes the clinical features of prostate cancer such as a Gleason score, serum PSA, and clinical stage to predict whether the tumor will be confined to the prostate. The tables are based on the accumulated experience of urologists performing radical prostatectomy at the James Buchanan Brady Urological Institute.
GRAPHIC REPORTING
QDx includes a graphic representation of the biopsy sample locations with the associated interpretation of each part including ultrasound guided needle biopsies and MRI Fusion biopsies.
MRI FUSION REPORT
PROSTATE REPORT
- American Cancer Society
Gleason Grading
Example Preview
Partin Table
Example Preview
Graphic Reporting
Example Preview
STI PANELS
Chlamydia trachomatis infections are one of the most common sexually transmitted infections worldwide. In the United States alone, an estimated 1,598,354 (497 cases per 100,000 population) new cases of CT infections were reported to the Centers for Disease Control in 2016. Using the Gen-Probe APTIMA COMBO 2 Assay for Chlamydia trachomatis and Neisseria gonorrhoeae, QDx Pathology can qualitatively detect and differentiate RNA to provide accurate identification of infection using the Thin Prep vial. The assay is more detailed and specific than a culture, allowing for rapid and reliable test results.
Turn Around Time: 48 hours
HPV TESTING
QDx HPV testing provides detection of human papillomavirus E6/E7 mRNA, histological localization of HPV within the tissue, and differentiation of low-risk vs. high-risk subtypes in formalin-fixed paraffin-embedded tissues.
Turn Around Time: 48 hours
QDx UTI pathogen panel is a PCR assay for the detection of microorganisms commonly associated with urinary tract infections. The assay also detects the presence of the most common antibiotic resistant genes.
- Turn Around Time: 24-48 hours
PATHOGENS
ANTIBIOTIC RESISTANT REPORTING
UTI PATHOGEN PANEL REPORT
The UTI Pathogen panel report is presented in an easy-to-read format with color keys indicating if any pathogen resistant genes are detected and provides the recommended antibiotic.
UTI Panel Report Components
Example Preview
Clinical Management Report
Upon request, QDx provides your practice with clinical management reports that summarize aggregate test result data to support your quality assurance process. Contact your QDx representative to learn more.
Clinical Management Report
Upon request, QDx provides your practice with clinical management reports that summarize aggregate test result data to support your quality assurance process. Contact your QDx representative to learn more.